Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

Contact Supplier

Bora Pharmaceuticals- Making success more certain.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers, 1 USDMF, 2 NDC API, 1 Listed Suppliers

2 API Suppliers
1 USDMF
2 NDC API
1 Listed Suppliers

INTERMEDIATES

7 Intermediates Suppliers

7 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

2 FDF Dossiers, 2 FDA Orange Book

2 FDF Dossiers
2 FDA Orange Book

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 90MG BASE, EMULSION;INTRAVENOUS - EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)

drugProductComposition
TABLET;ORAL - EQ 90MG BASE
EMULSION;INTRAVENOUS - EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)

RELATED EXCIPIENT COMPANIES

4 SPI Pharma, 2 Seqens, 3 DKSH, 2 Jai Radhe Sales, 5 Faran Shimi Pharmaceutical, 1 Boai NKY Pharmaceuticals Ltd, 12 Gangwal Healthcare, 4 Nanjing Well Pharmaceutical, 8 Actylis, 1 Aeon Procare, 7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 21 BASF, 5 Corel Pharma Chem, 5 DFE Pharma, 1 Finar, 11 Gangwal Chemicals, 3 Ideal Cures Pvt Ltd, 3 Ingredion Pharma Solutions, 21 Kerry, 10 Microlex e.U, 1 Nanjing Bold Chemical, 2 Nomisma Healthcare, 2 Novo Excipients, 2 Pharmatrans-Sanaq, 5 Pluviaendo, 3 Prachin Chemical, 16 Roquette, 7 Seppic, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 11 Sigachi Industries, 1 Ulanqab Kema New Material, 3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

62 Fillers, Diluents & Binders, 30 Direct Compression, 24 Solubilizers, 22 Coating Systems & Additives, 21 Disintegrants & Superdisintegrants, 19 Thickeners and Stabilizers, 17 Granulation, 17 Controlled & Modified Release, 16 Parenteral, 15 Co-Processed Excipients, 13 Lubricants & Glidants, 12 Topical, 7 Film Formers & Plasticizers, 7 Emulsifying Agents, 6 Taste Masking, 5 Chewable & Orodispersible Aids, 3 API Stability Enhancers, 3 Rheology Modifiers, 2 Surfactant & Foaming Agents, 2 Coloring Agents

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 11 NEWS #PharmaBuzz

media
2 DATA COMPILATION #PharmaFlow
11 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

globalSalesInformation
1 US Medicaid Prescriptions

MARKET PLACE

5 APIs

marketPlace
5 APIs

PATENTS & EXCLUSIVITIES

13 US Patents

patents
13 US Patents

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

7INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

820,442

Annual Reports (USD Million)

Finished Drug Prices

186 RELATED EXCIPIENT COMPANIES

303EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Rolapitant hydrochloride hydrate, 914462-92-3, Rolapitant hcl, Varubi, Sch619734, Rolapitant hcl h20

Molecular Formula

C₂₅H₂₉ClF₆N₂O₃

Molecular Weight

555.0 g/mol

InChI Key

GZQWMYVDLCUBQX-WVZIYJGPSA-N

FDA UNII

57O5S1QSAQ

Rolapitant Hydrochloride is the hydrochloride salt form of rolapitant, an orally bioavailable, centrally-acting, selective, neurokinin 1 receptor (NK1-receptor) antagonist with potential antiemetic activity. Upon oral administration, rolapitant competitively binds to and blocks the activity of the NK1-receptor in the central nervous system, thereby inhibiting the binding of the endogenous ligand, substance P (SP). This may prevent both SP-induced emesis and chemotherapy-induced nausea and vomiting (CINV). The interaction of SP with the NK1-receptor plays a key role in the induction of nausea and vomiting caused by emetogenic cancer chemotherapy. Compared to other NK1-receptor antagonists, rolapitant has both a more rapid onset of action and a much longer half-life.

1 2D Structure

Rolapitant HCl

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(5S,8S)-8-[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one;hydrate;hydrochloride

2.1.2 InChI

InChI=1S/C25H26F6N2O2.ClH.H2O/c1-16(17-11-19(24(26,27)28)13-20(12-17)25(29,30)31)35-15-23(18-5-3-2-4-6-18)10-9-22(14-32-23)8-7-21(34)33-22;;/h2-6,11-13,16,32H,7-10,14-15H2,1H3,(H,33,34);1H;1H2/t16-,22-,23-;;/m1../s1

2.1.3 InChI Key

GZQWMYVDLCUBQX-WVZIYJGPSA-N

2.1.4 Canonical SMILES

CC(C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OCC2(CCC3(CCC(=O)N3)CN2)C4=CC=CC=C4.O.Cl

2.1.5 Isomeric SMILES

C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)OC[C@]2(CC[C@]3(CCC(=O)N3)CN2)C4=CC=CC=C4.O.Cl

2.2 Other Identifiers

2.2.1 UNII

57O5S1QSAQ

2.3 Synonyms

2.3.1 MeSH Synonyms

1. (5s,8s)-8-(((1r)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4.5)decan-2-one

2. 8-((1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4,5)decan-2-one

3. Rolapitant

4. Sch 619734

5. Varubi

2.3.2 Depositor-Supplied Synonyms

1. Rolapitant Hydrochloride Hydrate

2. 914462-92-3

3. Rolapitant Hcl

4. Varubi

5. Sch619734

6. Rolapitant Hcl H20

7. Rolapitant Hydrochloride [usan]

8. Rolapitant Hydrochloride Monohydrate

9. 57o5s1qsaq

10. Varubi (tn)

11. (5s,8s)-8-(((1r)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-1,7-diazaspiro(4.5)decan-2-one Monohydrochloride Monohydrate

12. (5s,8s)-8-[[(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]methyl]-8-phenyl-1,9-diazaspiro[4.5]decan-2-one;hydrate;hydrochloride

13. Rolapitant Hydrochloride (usan)

14. Rolapitant Hcl Hydrate

15. 1,7-diazaspiro(4.5)decan-2-one, 8-(((1r)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)methyl)-8-phenyl-, Monohydrochloride, Monohydrate, (5s,8s)-

16. Unii-57o5s1qsaq

17. Rolapitant.hcl.h2o

18. Schembl2173125

19. Chembl3707330

20. Chebi:90911

21. Dtxsid70238570

22. Bcp15968

23. Mfcd19443696

24. Rolapitant Hydrochloride [mi]

25. Rolapitant Monohydrochloride Monohydrate

26. Ac-35397

27. Bs-17849

28. Rolapitant Hydrochloride [orange Book]

29. D08988

30. D83025

31. Rolapitant Hydrochloride Monohydrate [who-dd]

32. Q27162902

33. (5s,8s)-8-({(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}methyl)-2-oxo-8-phenyl-1,7-diazaspiro[4.5]decan-7-ium Chloride--water (1/1)

34. (5s,8s)-8-({(1r)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}methyl)-8-phenyl-1,7-diazaspiro[4.5]decan-2-one Hydrochloride--water (1/1)

2.4 Create Date

2007-07-09

3 Chemical and Physical Properties

Molecular Formula	C₂₅H₂₉ClF₆N₂O₃
Molecular Weight	555.0 g/mol
Hydrogen Bond Donor Count	4
Hydrogen Bond Acceptor Count	10
Rotatable Bond Count	5
Exact Mass	554.1770895 g/mol
Monoisotopic Mass	554.1770895 g/mol
Topological Polar Surface Area	51.4 Å²
Heavy Atom Count	37
Formal Charge	0
Complexity	731
Isotope Atom Count	0
Defined Atom Stereocenter Count	3
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	3

4 Pharmacology and Biochemistry

4.1 MeSH Pharmacological Classification

Neurokinin-1 Receptor Antagonists

Compounds that inhibit or block the activity of NEUROKININ-1 RECEPTORS. (See all compounds classified as Neurokinin-1 Receptor Antagonists.)

API SUPPLIERS

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Suppliers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

01

Chengdu Yazhong Bio-pharmaceutical

China

BOS Manchester

Not Confirmed

Not Confirmed

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - TABLET;ORAL - EQ 90MG BASE

USFDA APPLICATION NUMBER - 206500

DOSAGE - EMULSION;INTRAVENOUS - EQ 166.5MG BA...DOSAGE - EMULSION;INTRAVENOUS - EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)

USFDA APPLICATION NUMBER - 208399

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

Direct Compression

Solubilizers

Coating Systems & Additives

Disintegrants & Superdisintegrants

Thickeners and Stabilizers

Granulation

Controlled & Modified Release

Parenteral

Co-Processed Excipients

Lubricants & Glidants

Topical

Film Formers & Plasticizers

Emulsifying Agents

Taste Masking

Chewable & Orodispersible Aids

API Stability Enhancers

Rheology Modifiers

Surfactant & Foaming Agents

Coloring Agents

Digital Content

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

NEWS #PharmaBuzz

Global Sales Information

Do you need Business Intel? Ask us

US Medicaid Prescriptions

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Market Place

Do you need sourcing support? Ask us

APIs

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

US Patents

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Find Rolapitant HCl manufacturers, exporters & distributors on PharmaCompass

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers

1 USDMF

2 NDC API

1 Listed Suppliers

INTERMEDIATES

7 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

2 FDF Dossiers

2 FDA Orange Book

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 90MG BASE

EMULSION;INTRAVENOUS - EQ 166.5MG BASE/92.5ML (EQ 1.8MG BASE/ML)

RELATED EXCIPIENT COMPANIES

4 SPI Pharma

2 Seqens

3 DKSH

2 Jai Radhe Sales

5 Faran Shimi Pharmaceutical

1 Boai NKY Pharmaceuticals Ltd

12 Gangwal Healthcare

4 Nanjing Well Pharmaceutical

8 Actylis

1 Aeon Procare

7 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd

21 BASF

5 Corel Pharma Chem

5 DFE Pharma

1 Finar

11 Gangwal Chemicals

3 Ideal Cures Pvt Ltd

3 Ingredion Pharma Solutions

21 Kerry

10 Microlex e.U

1 Nanjing Bold Chemical

2 Nomisma Healthcare

2 Novo Excipients

2 Pharmatrans-Sanaq

5 Pluviaendo

3 Prachin Chemical

16 Roquette

7 Seppic

4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd

11 Sigachi Industries

1 Ulanqab Kema New Material

3 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

62 Fillers, Diluents & Binders

30 Direct Compression

24 Solubilizers

22 Coating Systems & Additives

21 Disintegrants & Superdisintegrants

19 Thickeners and Stabilizers

17 Granulation

17 Controlled & Modified Release

16 Parenteral

15 Co-Processed Excipients

13 Lubricants & Glidants

12 Topical

7 Film Formers & Plasticizers

7 Emulsifying Agents

6 Taste Masking

5 Chewable & Orodispersible Aids

3 API Stability Enhancers

3 Rheology Modifiers

2 Surfactant & Foaming Agents

2 Coloring Agents

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow

11 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions

MARKET PLACE

5 APIs

PATENTS & EXCLUSIVITIES